The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers

Authors

  • Danny Vesprini Department of Radiation Oncology, University of Toronto, Toronto, ON; Sunnybrook Odette Cancer Centre, Toronto, ON
  • Steven A. Narod Women’s College Research Institute, University of Toronto, Toronto, ON
  • John Trachtenberg Division of Urology, Department of Surgery, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON
  • Juanita Crook Department of Radiation Oncology, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON
  • Farid Jalali Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON
  • John Preiner Southlake Regional Cancer Centre, Newmarket, ON
  • Srikala Sridhar Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON; Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON
  • Robert G. Bristow Department of Radiation Oncology, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON

DOI:

https://doi.org/10.5489/cuaj.619

Abstract

Prostate cancers in patients with a mutation in BRCA2 have earlier
disease onset and an aggressive course, often necessitating
the use of systemic therapy. However, these tumours are DNA
repair-defective and could respond favourably to Parp inhibitors or
DNA-damaging agents, depending on the therapeutic ratio (ratio of
tumour response to normal tissue toxicity). We describe 3 patients
treated with precision radiotherapy or cisplatin who responded
favourably to both agents, yet did not suffer undue toxicity. We
review the concept of treating such patients with agents that are
selectively toxic to repair-deficient tumours.

Downloads

Download data is not yet available.

Author Biographies

Danny Vesprini, Department of Radiation Oncology, University of Toronto, Toronto, ON; Sunnybrook Odette Cancer Centre, Toronto, ON

Steven A. Narod, Women’s College Research Institute, University of Toronto, Toronto, ON

John Trachtenberg, Division of Urology, Department of Surgery, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON

Juanita Crook, Department of Radiation Oncology, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON

Farid Jalali, Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON

John Preiner, Southlake Regional Cancer Centre, Newmarket, ON

Srikala Sridhar, Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON; Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON

Robert G. Bristow, Department of Radiation Oncology, University of Toronto, Toronto, ON; Ontario Cancer BrCa2-mutated prostate cancers Institute/ Princess Margaret Hospital (University Health Network), Toronto, ON

Downloads

How to Cite

Vesprini, D., Narod, S. A., Trachtenberg, J., Crook, J., Jalali, F., Preiner, J., Sridhar, S., & Bristow, R. G. (2013). The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers. Canadian Urological Association Journal, 5(2), E31-E35. https://doi.org/10.5489/cuaj.619

Issue

Vol. 5 No. 2 (2011): April

Section

Case Report

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.